DexCom Common stock, shares issued (in shares) increased by 0.4% to $412.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.5%, from $410.30M to $412.30M. Over 4 years (FY 2020 to FY 2025), Common stock, shares issued (in shares) shows an upward trend with a 43.5% CAGR.
Increases indicate equity financing or stock-based compensation, while decreases result from share buybacks.
This represents the total number of shares that the company has distributed to shareholders. It includes both shares cur...
Used to calculate earnings per share and evaluate dilution trends compared to industry peers.
other_common_stock_shares_issued| Q2 '21 | Q3 '21 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $97.50M | $97.80M | $393.20M | $394.60M | $405.50M | $407.20M | $408.50M | $408.50M | $408.80M | $408.90M | $410.30M | $410.40M | $410.60M | $410.70M | $412.30M |
| QoQ Change | — | +0.3% | +302.0% | +0.4% | +2.8% | +0.4% | +0.3% | +0.0% | +0.1% | +0.0% | +0.3% | +0.0% | +0.0% | +0.0% | +0.4% |
| YoY Change | — | — | — | — | — | +3.6% | — | +3.5% | +0.8% | +0.4% | +0.4% | +0.5% | +0.4% | +0.4% | +0.5% |